Form 4: Turnstone Biologics Director Jerel Davis Acquires Stock Options

Director Jerel Davis of Turnstone Biologics Corp. acquired stock options exercisable for 12,770 shares of common stock on June 3, 2024.

Summary

• Jerel Davis, a director of Turnstone Biologics Corp., filed a Form 4 indicating a change in beneficial ownership.
• On June 3, 2024, Davis acquired stock options for 12,770 shares of Turnstone Biologics Corp. common stock at an exercise price of $2.69 per share.
• The options vest on the earlier of June 3, 2025, or the date of the next annual meeting of stockholders, contingent upon Davis's continuous service.
• Following the transaction, Davis directly owns options for 12,770 shares.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to insider transactions, indicating a neutral sentiment.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in the biopharmaceutical industry. Monitoring such filings can provide insights into management's sentiment and alignment with shareholder interests.

Stakeholder Impact

• The acquisition of stock options by a director can align management's interests with those of shareholders.

Key Dates

Keywords

Form 4, beneficial ownership, stock options, Turnstone Biologics, TSBX, Jerel Davis, director